Patents by Inventor Guizhong Liu
Guizhong Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240141046Abstract: Provided herein are cross-reactive antibodies (or antigen binding fragments thereof) that bind to human CTLA4, activatable antibodies that bind to human CTLA4, nucleic acid molecules encoding the same, pharmaceutical compositions thereof, and methods of their therapeutic use (e.g., for treatment of cancer).Type: ApplicationFiled: May 18, 2023Publication date: May 2, 2024Applicant: Adagene Inc.Inventors: Peter Peizhi LUO, Fangyong DU, Zhongzong PAN, Guizhong LIU
-
Patent number: 11859003Abstract: Provided are antibodies that bind to human CD137 or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, and for the treatment of cancer.Type: GrantFiled: August 21, 2018Date of Patent: January 2, 2024Assignee: Adagene Inc.Inventors: Peter Peizhi Luo, Fangyong Du, Guizhong Liu, Yan Li, Jun Chen, Xiaohong She, Peter Cheung
-
Publication number: 20230242663Abstract: The present application provides compositions and methods for treating cancers in a subject using an anti-CD137 antibody and an agent that induces expression of CD137 on an immune cell and/or induces expression of CD137L on a cancer cell of the subject. In some embodiments, the agent is a cytokine such as IL-2. In some embodiments, the agent is a histone deacetylase (HDAC) inhibitor. In some embodiments, the agent is a DNA-damaging agent.Type: ApplicationFiled: June 23, 2021Publication date: August 3, 2023Applicant: Adagene PTE. LTD.Inventors: Peter Peizhi LUO, Guizhong LIU, Aaron NGUYEN
-
Patent number: 11692036Abstract: Provided herein are cross-reactive antibodies (or antigen binding fragments thereof) that bind to human CTLA4, activatable antibodies that bind to human CTLA4, nucleic acid molecules encoding the same, pharmaceutical compositions thereof, and methods of their therapeutic use (e.g., for treatment of cancer).Type: GrantFiled: February 2, 2019Date of Patent: July 4, 2023Assignee: Adagene Inc.Inventors: Peter Peizhi Luo, Fangyong Du, Zhongzong Pan, Guizhong Liu
-
Publication number: 20230203170Abstract: The disclosure relates to antibodies against human CSF-1R, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: December 23, 2020Publication date: June 29, 2023Inventors: Fangyong Du, Peter Peizhi Luo, Yan Li, Guizhong Liu, Xiaohong She, Zhengxi Dai
-
Publication number: 20230133118Abstract: The present application provides compositions and methods for treating cancers, including follicular lymphoma, T cell lymphoma and adenoid cystic carcinoma, using an anti-CD137 antibody that specifically binds to an extracellular domain of human CD137. In some embodiment, combination therapies including the anti-CD137 antibody and an immune checkpoint inhibitor, and/or a chemotherapeutic agent are provided. Biomarkers such as total CD137, membrane bound CD137 (mCD137), soluble CD137 (sCD137), CD137 ligand, Ki67, CD8+ effector memory T (Tem) cells, regulatory T (Treg) cells, and natural killer (NK) cell levels for the methods of treatment described herein are also provided.Type: ApplicationFiled: May 13, 2021Publication date: May 4, 2023Applicant: Adagene AGInventors: Peter Peizhi LUO, Guizhong LIU, Changhua GONG
-
Publication number: 20230124669Abstract: Provided are heterodimeric proteins comprising polypeptides having CH3 domains with engineered residues that form disulfide bonds and/or salt bridges. Also provided are activatable antibodies targeting CD3 and/or HER2. Compositions, methods of manufacture and methods of treatment using the heterodimeric proteins and the activatable antibodies are further provided.Type: ApplicationFiled: January 22, 2021Publication date: April 20, 2023Applicants: Adagene AGInventors: Peter Peizhi LUO, Fangyong DU, Guizhong LIU, Zhengxi DAI, Jianfeng SHI, Zhixiong LIN, Yan LI
-
Publication number: 20220204637Abstract: The present disclosure provides antibodies that bind to human CD137 or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, and for the treatment of cancer.Type: ApplicationFiled: December 28, 2021Publication date: June 30, 2022Applicant: Adagene Inc.Inventors: Peter Peizhi LUO, Fangyong DU, Yan LI, Guizhong LIU, Jun CHEN, Xiaohong SHE, Peter CHEUNG
-
Patent number: 11359016Abstract: Provided herein are cross-reactive antibodies (or antigen binding fragments thereof) that bind to human CTLA4, activatable antibodies that bind to human CTLA4, nucleic acid molecules encoding the same, pharmaceutical compositions thereof, and methods of their therapeutic use (e.g., for treatment of cancer).Type: GrantFiled: February 1, 2019Date of Patent: June 14, 2022Assignee: ADAGENE INC.Inventors: Peter Peizhi Luo, Fangyong Du, Zhongzong Pan, Guizhong Liu
-
Publication number: 20220089757Abstract: Provided herein are antibodies that bind to an intracellular/transmembrane portion of human CD137L, as well as methods relating to the use of these antibodies for detecting CD137L expression in a sample and the detection of CD137L expression as a biomaker for cancer treatment.Type: ApplicationFiled: June 4, 2020Publication date: March 24, 2022Applicant: ADAGENE PTE. LTD.Inventors: Peter Peizhi LUO, Fangyong DU, Guizhong LIU
-
Patent number: 11242395Abstract: The present disclosure provides antibodies that bind to human CD137 or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, and for the treatment of cancer.Type: GrantFiled: August 21, 2018Date of Patent: February 8, 2022Assignee: Adagene Inc.Inventors: Peter Peizhi Luo, Fangyong Du, Yan Li, Guizhong Liu, Jun Chen, Xiaohong She, Peter Cheung
-
Publication number: 20210206855Abstract: Provided herein are cross-reactive antibodies (or antigen binding fragments thereof) that bind to human CTLA4, activatable antibodies that bind to human CTLA4, nucleic acid molecules encoding the same, pharmaceutical compositions thereof, and methods of their therapeutic use (e.g., for treatment of cancer).Type: ApplicationFiled: February 2, 2019Publication date: July 8, 2021Applicant: Adagene Inc.Inventors: Peter Peizhi LUO, Fangyong DU, Zhongzong PAN, Guizhong LIU
-
Publication number: 20210122824Abstract: The present disclosure provides antibodies that bind to the T-cell co-inhibitor ligand programmed death-ligand1 (PD-L1) protein, and methods of use. In various embodiments of the disclosure, the antibodies are fully human antibodies that bind to PD-L1. In certain embodiments, the present disclosure provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-L1 and a second binding specificity that binds to a tumor cell antigen, an infected cell-specific antigen, or a T-cell co-inhibitor. In some embodiments, the antibodies of the disclosure are useful for inhibiting or neutralizing PD-L1 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.Type: ApplicationFiled: March 29, 2019Publication date: April 29, 2021Inventors: Peizhi Luo, Fangyong Du, Guizhong Liu, Yan Li
-
Publication number: 20200377608Abstract: Provided herein are methods relating to the use of CD137 Ligand (CD137L) expression; methods relating to the use of CD137L expression as a biomarker; and methods for predicting, assessing, and/or aiding in assessment of responsiveness of a subject in need thereof to treatment with particular anti-cancer therapies (e.g., an anti-CD137 antibody, a checkpoint blockade immunotherapy).Type: ApplicationFiled: November 30, 2018Publication date: December 3, 2020Applicant: Adagene Inc.Inventors: Peter Peizhi LUO, Guizhong LIU, Fangyong DU
-
Publication number: 20200369776Abstract: Provided are antibodies that bind to human CD137 or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, and for the treatment of cancer.Type: ApplicationFiled: August 21, 2018Publication date: November 26, 2020Applicant: Adagene Inc.Inventors: Peter Peizhi LUO, Fangyong DU, Guizhong LIU, Yan LI, Jun CHEN, Xiaohong SHE, Peter CHEUNG
-
Publication number: 20190241662Abstract: Provided herein are cross-reactive antibodies (or antigen binding fragments thereof) that bind to human CTLA4, activatable antibodies that bind to human CTLA4, nucleic acid molecules encoding the same, pharmaceutical compositions thereof, and methods of their therapeutic use (e.g., for treatment of cancer).Type: ApplicationFiled: February 1, 2019Publication date: August 8, 2019Applicant: ADAGENE INC.Inventors: Peter Peizhi LUO, Fangyong DU, Zhongzong PAN, Guizhong LIU
-
Publication number: 20190055314Abstract: The present disclosure provides antibodies that bind to human CD137 or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, and for the treatment of cancer.Type: ApplicationFiled: August 21, 2018Publication date: February 21, 2019Applicant: Adagene Inc.Inventors: Peter Peizhi Luo, Fangyong Du, Yan Li, Guizhong Liu, Jun Chen, Xiaohong She, Peter Cheung